Relay Therapeutics Q1 2026 net loss $73.3M; FDA BTD for zovegalisib; cash $642M

Relay Therapeutics, Inc.

2026-Q1 EPS reported -$0.41 revenue$3,000,000

FDA granted Breakthrough Therapy designation to zovegalisib+fulvestrant for PIK3CA-mutant HR+/HER2- advanced breast cancer.
Median PFS 11.1 months in heavily pre-treated patients; similar efficacy across kinase and non-kinase mutations.
Phase 3 1L trial of zovegalisib+atirmociclib expected early 2027; Pfizer to supply atirmociclib.
Initiated Phase 1/2 trial of RLY-8161, an NRAS-selective inhibitor, in NRAS-mutant solid tumors.
Cash, cash equivalents and investments $642.1M; net loss $73.3M ($0.41 per share) for Q1 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Relay Therapeutics, Inc. reported first quarter ended March 31, 2026 results: revenue 3.0, net income -73.3, EPS -0.41.

Period: first quarter ended March 31, 2026
Revenue: 3.0
Net income: -73.3
EPS: -0.41
Result: reported results

Exact text from the filing

--- EX-99.1 Exhibit 99.1 Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates FDA Breakthrough Therapy designation granted to zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial population in 2L breast cancer Presented zovegalisib doublet data at Phase 3 dose in CDK4/6-experienced

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Relay Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-206398

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.